Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $11.17.

A number of equities analysts have commented on the company. Leerink Partners lowered Compass Therapeutics from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $5.00 to $4.00 in a research note on Friday, November 15th. Leerink Partnrs lowered Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, November 15th. Jefferies Financial Group boosted their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Monday. D. Boral Capital reissued a "buy" rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, January 8th.

Compass Therapeutics Trading Down 2.0 %

CMPX stock traded down $0.07 during trading on Tuesday, hitting $3.38. The company had a trading volume of 608,060 shares, compared to its average volume of 2,260,618. The company has a fifty day moving average price of $2.28 and a two-hundred day moving average price of $1.80. The company has a market cap of $465.05 million, a P/E ratio of -9.13 and a beta of 1.17. Compass Therapeutics has a fifty-two week low of $0.76 and a fifty-two week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03. On average, analysts expect that Compass Therapeutics will post -0.35 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in CMPX. Renaissance Technologies LLC raised its position in shares of Compass Therapeutics by 99.7% during the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company's stock worth $141,000 after acquiring an additional 70,200 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in Compass Therapeutics in the second quarter valued at about $41,000. SG Americas Securities LLC increased its holdings in Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company's stock valued at $71,000 after purchasing an additional 5,515 shares during the last quarter. Rovin Capital UT ADV bought a new stake in Compass Therapeutics in the third quarter valued at about $25,000. Finally, Intech Investment Management LLC bought a new stake in Compass Therapeutics in the third quarter valued at about $30,000. Institutional investors own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.